CA3033184C - Beta-amino-isoquinolinyl amide compounds - Google Patents
Beta-amino-isoquinolinyl amide compounds Download PDFInfo
- Publication number
- CA3033184C CA3033184C CA3033184A CA3033184A CA3033184C CA 3033184 C CA3033184 C CA 3033184C CA 3033184 A CA3033184 A CA 3033184A CA 3033184 A CA3033184 A CA 3033184A CA 3033184 C CA3033184 C CA 3033184C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- enantiomer
- diastereomer
- acceptable salt
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662377219P | 2016-08-19 | 2016-08-19 | |
| US62/377,219 | 2016-08-19 | ||
| PCT/US2017/025609 WO2018034702A1 (en) | 2016-08-19 | 2017-03-31 | Beta-amino-isoquinolinyl amide compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3033184A1 CA3033184A1 (en) | 2018-02-22 |
| CA3033184C true CA3033184C (en) | 2024-06-04 |
Family
ID=61191217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3033184A Active CA3033184C (en) | 2016-08-19 | 2017-03-31 | Beta-amino-isoquinolinyl amide compounds |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9963432B2 (https=) |
| EP (1) | EP3500251A4 (https=) |
| JP (1) | JP2019529359A (https=) |
| KR (1) | KR20190039587A (https=) |
| CN (1) | CN109640971A (https=) |
| AU (1) | AU2017312712B2 (https=) |
| BR (1) | BR112019003232A2 (https=) |
| CA (1) | CA3033184C (https=) |
| MX (1) | MX2019002019A (https=) |
| WO (1) | WO2018034702A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| EP3053913B1 (en) | 2009-05-01 | 2018-03-07 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
| DK3811943T3 (da) | 2013-03-15 | 2023-04-03 | Aerie Pharmaceuticals Inc | Forbindelse til anvendelse til behandling af øjenlidelser |
| KR102568079B1 (ko) | 2016-08-31 | 2023-08-17 | 에어리 파마슈티컬즈, 인코포레이티드 | 안과용 조성물 |
| KR20190135027A (ko) | 2017-03-31 | 2019-12-05 | 에어리 파마슈티컬즈, 인코포레이티드 | 아릴 시클로프로필-아미노-이소퀴놀리닐 아미드 화합물 |
| BR112020020008A2 (pt) * | 2018-03-30 | 2021-01-05 | Aerie Pharmaceuticals, Inc. | Sais mono ácido de 6-aminoisoquinolinas e seus usos |
| WO2020047496A1 (en) * | 2018-08-31 | 2020-03-05 | Aerie Pharmaceuticals, Inc. | Isoquinoline-steroid conjugates and uses thereof |
| AU2019337703B2 (en) | 2018-09-14 | 2023-02-02 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
| WO2021001713A1 (en) * | 2019-06-29 | 2021-01-07 | Micro Labs Limited | Process for the preparation of (s)-netarsudil, its salts & polymorphs |
| ES3015621T3 (en) * | 2019-12-31 | 2025-05-06 | Ind Tech Res Inst | Beta-amino acid derivative, kinase inhibitor and pharmaceutical composition containing the same, and use of the same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8455513B2 (en) * | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| US8450344B2 (en) * | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| EP3053913B1 (en) * | 2009-05-01 | 2018-03-07 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
| DK3811943T3 (da) * | 2013-03-15 | 2023-04-03 | Aerie Pharmaceuticals Inc | Forbindelse til anvendelse til behandling af øjenlidelser |
| US9643927B1 (en) * | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
| US10550087B2 (en) * | 2015-11-17 | 2020-02-04 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
-
2017
- 2017-03-31 BR BR112019003232A patent/BR112019003232A2/pt not_active Application Discontinuation
- 2017-03-31 JP JP2019509467A patent/JP2019529359A/ja active Pending
- 2017-03-31 CN CN201780050718.3A patent/CN109640971A/zh active Pending
- 2017-03-31 CA CA3033184A patent/CA3033184C/en active Active
- 2017-03-31 EP EP17841778.8A patent/EP3500251A4/en not_active Withdrawn
- 2017-03-31 MX MX2019002019A patent/MX2019002019A/es unknown
- 2017-03-31 WO PCT/US2017/025609 patent/WO2018034702A1/en not_active Ceased
- 2017-03-31 KR KR1020197007986A patent/KR20190039587A/ko not_active Ceased
- 2017-03-31 AU AU2017312712A patent/AU2017312712B2/en not_active Ceased
- 2017-03-31 US US15/476,850 patent/US9963432B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017312712A1 (en) | 2019-02-21 |
| EP3500251A4 (en) | 2020-04-08 |
| KR20190039587A (ko) | 2019-04-12 |
| JP2019529359A (ja) | 2019-10-17 |
| BR112019003232A2 (pt) | 2019-06-18 |
| EP3500251A1 (en) | 2019-06-26 |
| CA3033184A1 (en) | 2018-02-22 |
| US9963432B2 (en) | 2018-05-08 |
| WO2018034702A1 (en) | 2018-02-22 |
| AU2017312712B2 (en) | 2019-12-12 |
| CN109640971A (zh) | 2019-04-16 |
| US20180050990A1 (en) | 2018-02-22 |
| MX2019002019A (es) | 2019-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3033184C (en) | Beta-amino-isoquinolinyl amide compounds | |
| US11021456B2 (en) | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | |
| US10899714B2 (en) | 6-aminoisoquinoline compounds | |
| CA2712443C (en) | 6- and 7-amino isoquinoline compounds and methods for making and using the same | |
| US7671205B2 (en) | 6-aminoisoquinoline compounds | |
| WO2018183911A1 (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
| WO2021050994A1 (en) | Heterobicyclic carboxamides and uses thereof | |
| WO2020176579A1 (en) | Thienyl cyclopropyl-amino-isoquinolinyl amide compounds | |
| HK40007624A (en) | Beta-amino-isoquinolinyl amide compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220331 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20240827 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241224 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241224 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250124 |